Cognitive functions in patients with atrial fibrillation at baseline and at different stages after pacemaker implantation depending on the received anticoagulant therapy

Abstract

Aim. Comparative assessment of cognitive functions (memory, attention, cognition and neurodynamics) in patients with atrial fibrillation before and at different stages after implantation of permanent pacemaker depending on the received anticoagulant therapy.

Methods. We examined 44 patients (average age 65.5 ± 2.5 years) with ischemic heart disease (IHD) complicated by persistent or paroxysmal atrial fibrillation, which required implantation of a permanent pacemaker (PM). The patients were divided into 2 groups: receiving warfarin (28 patients - 63.6 %, average age 65.5 ± 1.6 years) and those who received oral anticoagulants (OAC) (16 patients - 36.4 %, average age 66.3 ± 1.4 years, p = 0.614). To assess the cognitive functions, psycho-physiological complex «Status PF» was used.

Results. Before PM implantation, the patients of both groups had decreased indices of visual memory. On days 5-7 after PM implantation, each group showed its increase (p = 0.001 and p = 0.013, respectively). On days 30-40, patients receiving warfarin developed a dramatic decrease of visual memory compared to the previous data and they became reliably lower than in the control group (p = 0.001). In the group receiving OAC, visual memory stayed unchanged (p = 0.076). Similar changes in warfarin group occurred at the assessment of auditory memory and attention volume (p = 0.001). Cognition indices (difficult analogues) were worse at baseline in warfarin group than in the group of OAC (7.0 ± 0.5 и 9.6 ± 0.6, р1 = 0.003) and this interrelation persisted on two following examinations (9.5 ± 0.4 and 10.8 ± 0.4, р1 = 0.041; 8.5 ± 0.4 and 9.8 ± 0.4, р1 = 0.048). Before PM implantation, the patients of both groups required more time of average exposure for neurodynamics test than in the control group (р = 0.001 and р = 0.002 respectively). On days 5-7 after PM implantation, the average exposure time decreased in both groups and they had no differences between each other and with the control (р1 = 0.132, р = 0.934 and р = 0.058). At the second testing only warfarin group had increased the mentioned time, and it exceeded the same parameter in the OAC group (p = 0.007).

Conclusion. A comparative assessment of cognitive functions in patients with IHD and atrial fibrillation demonstrated that in the warfarin group and the group receiving OAC patients had cognitive deficit more profound in the patients receiving warfarin. Those differences persisted at different stages after permanent PM implantation.

Keywords

atrial fibrillation cognitive functions / permanent pacemaker / anticoagulant therapy

References

[1] Kirchhof P., Benussi S., Kotecha D., et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016; 37 (38): 2893–2962. DOI: 10.1093/eurheartj/ehw210.

[2] Kirchhof P., Benussi S., Kotecha D., et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016; 37 (38): 2893-2962. DOI: 10.1093/eurheartj/ehw210.

[3] Udompanich S., Lip G.Y., Apostolakis S., et al. At­rial fibrillation as a risk factor for cognitive impairment: a semi-systematic review. Q. J. Med. 2013; 106: 795–802. DOI: 10.1093/qjmed/hct129.

[4] Udompanich S., Lip G.Y., Apostolakis S., et al. Atrial fibrillation as a risk factor for cognitive impairment: a semi-systematic review. Q. J. Med. 2013; 106: 795-802. DOI: 10.1093/qjmed/hct129.

[5] Klinicheskie rekomendacii po provedeniju elektrofiziolo­gicheskih issledovanij, kateternoy abljacii i primeneniju implantiruemyh antiaritmicheskih ustrojstv. (Clinical guidelines on electrophisiological studies, catheter ablation and use of implanted antiarrhythmic devices.) Moskow. 2013; 597 р. (In Russ.)

[6] Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. М.: ООО ИНТРЕНД, 2013; 597 с.

[7] Lippil G., Mattiuzzi C., Cervellin G., et al. Direct oral anticoagulants: analysis of worldwide use and popularity using Google Trends. Ann. Transl. Med. 2017; 5 (16): ­322–330. DOI: 10.21037/atm.2017.06.65.

[8] Lippil G., Mattiuzzi C., Cervellin G., et al. Direct oral anticoagulants: analysis of worldwide use and popularity using Google Trends. Ann. Transl. Med. 2017; 5 (16): 322-330. DOI: 10.21037/atm.2017.06.65.

[9] Dagres N., Chao T.F., Fenelon G., et al. European Heart Rhythm Association (EHRA) / Heart Rhythm Society (HRS) / Asia Pacific Heart Rhythm Society (APHRS) / Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice? Europace. 20 (9): 1399–1421. DOI: 10.1093/europace/euy046.

[10] Dagres N., Chao T.F., Fenelon G., et al. European Heart Rhythm Association (EHRA) / Heart Rhythm Society (HRS) / Asia Pacific Heart Rhythm Society (APHRS) / Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice? Europace. 20 (9): 1399-1421. DOI: 10.1093/europace/euy046.

[11] Alonso A., Arenas de Larriva A.P. Atrial Fibrillation, Cognitive Decline And Dementia. Eur. Cardiol. J. 2016; 11 (1): 49–53. DOI: 10.15420/ecr.2016:13:2.

[12] Alonso A., Arenas de Larriva A.P. Atrial Fibrillation, Cognitive Decline And Dementia. Eur. Cardiol. J. 2016; 11 (1): 49-53. DOI: 10.15420/ecr.2016:13:2.

[13] Singh-Manoux A., Fayosse A., Sabia S., et al. Atrial fibrillation as a risk factor for cognitive decline and dementia. Eur. Heart. J. 2017; 38 (34): 2612–2618. DOI: 10.1093/eurheartj/ehx208.

[14] Singh-Manoux A., Fayosse A., Sabia S., et al. Atrial fibrillation as a risk factor for cognitive decline and dementia. Eur. Heart. J. 2017; 38 (34): 2612-2618. DOI: 10.1093/eurheartj/ehx208.

[15] Marinigh R., Lip G.Y.H., Fiotti N., et al. Age as a risk factor for stroke in atrial fibrillation patients implications for thromboprophylaxis: Implications for thromboprophylaxis. J. Am. Coll. Cardiol. 2010; 56: 827–837. DOI: 10.1016/

[16] Marinigh R., Lip G.Y.H., Fiotti N., et al. Age as a risk factor for stroke in atrial fibrillation patients implications for thromboprophylaxis: Implications for thromboprophylaxis. J. Am. Coll. Cardiol. 2010; 56: 827-837. DOI: 10.1016/ j.jacc.2010.05.028.

[17] j.jacc.2010.05.028.

[18] Stefansdottir H., Arnar D.O., Aspelund Th., еt al. Atrial fibrillation is associated with reduced brain volume and cognitive function independent of cerebral infarcts. Stroke. 2013; 44 (4): 1020-1025. DOI: 10.1161/STROKEAHA.12.679381.

[19] Stefansdottir H., Arnar D.O., Aspelund Th., еt al. Atrial fibrillation is associated with reduced brain volume and cognitive function independent of cerebral infarcts. Stroke. 2013; 44 (4): 1020–1025. DOI: 10.1161/­

[20] Scarsoglio S., Saglietto A., Anselmino M. Alteration of cerebrovascular haemodynamic patterns due to atrial fibrillation: an in silico investigation. J. R. Soc. Interface. 2017; 14 (129): 170-180. DOI: 10.1098/rsif.2017.0180.

[21] STROKEAHA.12.679381.

[22] Bunch T.J., May H.T., Bair T.L., et al. Atrial Fibrillation Patients Treated With Long-Term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared With Patients Receiving Long-Term Warfarin for Other Indications. J. Am. Heart. Assoc. 2016; 5 (7): e003932. DOI: 10.1161/JAHA.116.003932.

[23] Scarsoglio S., Saglietto A., Anselmino M. Alte­ration of cerebrovascular haemodynamic patterns due to atrial fibrillation: an in silico investigation. J. R. Soc. Interface. 2017; 14 (129): 170–180. DOI: 10.1098/rsif.2017.0180.

[24] Ефимова Н.Ю., Чернов В.И., Ефимова И.Ю. и др. Влияние имплантации электрокардиостимулятора на когнитивную дисфункцию у пациентов с постоянной формой фибрилляции предсердий: взаимосвязь с церебральной перфузией. Вестник аритмологии. 2008; 54: 15-19.

[25] Bunch T.J., May H.T., Bair T.L., et al. Atrial Fibrillation Patients Treated With Long-Term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared With Patients Receiving Long-Term Warfarin for Other Indications. J. Am. Heart. Assoc. 2016; 5 (7): e003932. doi: 10.1161/JAHA.116.003932.

[26] Скопецкая С.А., Давидович И.М., Неаполитанская Т.Э. Состояние когнитивных функций у пациентов с пароксизмальной и постоянной формами фибрилляции предсердий исходно и в разные сроки после имплантации постоянного электрокардиостимулятора. Вестник аритмологии. 2016; 85: 34-40.

[27] Efimova N.Yu., Chernov V.I., Efimova I.Yu., et al. Effect of cardiac pacemaker implantation on cognitive dysfunction in patients with chronic atrial fibrillation: interrelation with cerebral perfusion. Vestnik aritmologii. 2008; 54: 15–19. (In Russ.)

[28] Тарасова И.В., Трубникова О.А., Кухарева И.Н. Методические подходы к диагностике послеоперационной когнитивной дисфункции в кардиохирургической клинике. Комплексные проблемы сердечно-сосудистых заболеваний. 2015; 4: 73-78.

[29] Skopetskaya S.A., Davidovich I.M., Neapolitanskaya T.E. Cognitive function in patients with paroxysmal and permanent atrialfibrillation before and at different stages after permanent pacemaker implantation. Vestik aritmologii. 2016; 85: 34–40. (In Russ.)

[30] Jacobs V., May H.T., Bair T.L., et al. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation. Am. J. Cardiol. 2016; 118 (2): 210-214. DOI: 10.1016/j.amjcard.2016.04.039.

[31] Tarasova I.V., Trubnikova O.A., Kuhareva I.N. Methodological approaches to the diagnosis of postoperative cognitive dysfunction in cardiac surgery clinic. Kompleksnye problemy serdechno-sosu­distykh zabolevaniy. 2015; 4: 73–78. (In Russ.)

[32] Jacobs V., May H.T., Bair T.L., et al. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation. Am. J. Cardiol. 2016; 118 (2): 210–214. DOI: 10.1016/j.amjcard.2016.04.039.

RIGHTS & PERMISSIONS

Davidovich I.M., Skopetskaya S.A., Neapolitanskaya T.E., Zharskiy S.L.